Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M67,399Revenue $M20,247Net Margin (%)10.8Z-Score3.7
Enterprise Value $M70,928EPS $1.5Operating Margin %13.0F-Score6
P/E(ttm))37.1Cash Flow Per Share $6.7Pre-tax Margin (%)12.6Higher ROA y-yN
Price/Book3.110-y EBITDA Growth Rate %0.4Quick Ratio1.3Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %-16.9Current Ratio1.5Lower Leverage y-yN
Price/Cash Flow9.8y-y EBITDA Growth Rate %81.7ROA % (ttm)6.4Higher Current Ratio y-yN
Dividend Yield %1.9Insider Buy (3m)0ROE % (ttm)11.5Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M1,506ROI % (ttm)9.7Gross Margin Increase y-yY

Gurus Latest Trades with ABT

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABTRay Dalio 2014-12-31 Buy 0.02%$39.99 - $46.37
($43.58)
$ 47.379%New holding, 45000 sh.45,000
ABTKen Fisher 2014-12-31 Add$39.99 - $46.37
($43.58)
$ 47.379%Add 22.8%13,828
ABTMason Hawkins 2014-12-31 Reduce-0.79%$39.99 - $46.37
($43.58)
$ 47.379%Reduce -28.08%8,977,941
ABTGeorge Soros 2014-12-31 Reduce-0.06%$39.99 - $46.37
($43.62)
$ 47.379%Reduce -24.46%602,181
ABTMario Gabelli 2014-12-31 Reduce-0.01%$39.99 - $46.37
($43.58)
$ 47.379%Reduce -33.96%65,337
ABTKen Fisher 2014-09-30 Reduce$41.05 - $43.69
($42.33)
$ 47.3712%Reduce -37.53%11,261
ABTMason Hawkins 2014-09-30 Reduce-0.26%$41.05 - $43.69
($42.33)
$ 47.3712%Reduce -8.8%12,483,566
ABTRay Dalio 2014-09-30 Sold Out -0.01%$41.05 - $43.69
($42.33)
$ 47.3712%Sold Out0
ABTMario Gabelli 2014-09-30 Reduce-0.01%$41.05 - $43.69
($42.33)
$ 47.3712%Reduce -38.44%98,937
ABTJean-Marie Eveillard 2014-06-30 Buy 0.16%$37.02 - $41
($39.24)
$ 47.3721%New holding, 1665688 sh.1,665,688
ABTKen Fisher 2014-06-30 Add$37.02 - $41
($39.24)
$ 47.3721%Add 106.12%18,027
ABTGeorge Soros 2014-06-30 Reduce-0.11%$37.02 - $41
($39.24)
$ 47.3721%Reduce -23.73%932,181
ABTRichard Pzena 2014-03-31 Add0.11%$35.85 - $40.12
($38.5)
$ 47.3723%Add 7.9%6,934,282
ABTGeorge Soros 2014-03-31 Add0.1%$35.85 - $40.12
($38.54)
$ 47.3723%Add 25.97%1,222,181
ABTRay Dalio 2014-03-31 Buy 0.01%$35.85 - $40.12
($38.54)
$ 47.3723%New holding, 17200 sh.17,200
ABTDaniel Loeb 2014-03-31 Sold Out -2.1%$35.85 - $40.12
($38.54)
$ 47.3723%Sold Out0
ABTDaniel Loeb 2013-12-31 Buy 2.1%$33.01 - $38.71
($36.89)
$ 47.3728%New holding, 3250000 sh.3,250,000
ABTRobert Olstein 2013-12-31 Add0.19%$33.01 - $38.71
($36.89)
$ 47.3728%Add 23.45%179,000
ABTMario Gabelli 2013-12-31 Add0.02%$33.01 - $38.71
($36.89)
$ 47.3728%Add 110.21%197,183
ABTRay Dalio 2013-12-31 Sold Out -0.03%$33.01 - $38.71
($36.89)
$ 47.3728%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABT is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ABT Ray Dalio 2014-12-3145,00000.02New Buy
ABT Ken Fisher 2014-12-3113,82800+22.8%
ABT PRIMECAP Management 2014-12-3117,638,0841.170.8+3.21%
ABT Robert Bruce 2014-12-31230,9150.022.9+0.7%
ABT Vanguard Health Care Fund 2014-12-317,591,4000.50.8
ABT Robert Olstein 2014-12-31179,0000.010.98-1.65%
ABT Richard Pzena 2014-12-316,860,4390.461.7-5.86%
ABT Dodge & Cox 2014-12-3137,06800-6.46%
ABT Jean-Marie Eveillard 2014-12-311,250,9560.080.14-12.33%
ABT George Soros 2014-12-31602,1810.040.3-24.46%
ABT Mason Hawkins 2014-12-318,977,9410.62.3-28.08%
ABT Mario Gabelli 2014-12-3165,33700.02-33.96%
Premium Most recent portfolio changes are included for Premium Members only!


ABT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Contreras JaimeSenior Vice President 2015-02-18Sell423$46.262.4view
Simhambhatla Murthy VSenior Vice President 2015-02-17Sell172$46.412.07view
ALLEN HUBERT LExecutive Vice President 2015-02-17Sell172$46.382.13view
Pavee Jean-YvesSenior Vice President 2015-02-17Sell621$46.412.07view
CAPEK JOHN MExecutive Vice President 2015-02-04Sell9,935$45.833.36view
CAPEK JOHN MExecutive Vice President 2015-02-04Sell38,773$45.763.52view
CAPEK JOHN MExecutive Vice President 2015-02-04Sell34,292$45.663.75view
Contreras JaimeSenior Vice President 2014-11-25Sell51,600$44.077.49view
Contreras JaimeSenior Vice President 2014-11-10Sell6,300$43.688.45view
WHITE MILES DChairman and CEO 2014-10-29Sell440,800$42.5211.41view

Press Releases about ABT :

    Quarterly/Annual Reports about ABT:

    News about ABT:

    Articles On GuruFocus.com
    AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
    What Could Be The Major Highlights In AbbVie’s Upcoming Earnings Call? Jan 29 2015 
    Feeling Good With This Med Company Jan 20 2015 
    Diamond Hill Adds Two Companies to Portfolio in Third Quarter Dec 11 2014 
    Boston Scientific Lost the First Place in Innovation Dec 11 2014 
    Top 7 Dividend Aristocrats: The Best of The Best Dec 10 2014 
    6 Stocks Giving Investors Potential Dividend Hikes In December Dec 04 2014 
    Dividend Aristocrats In Focus Part 45: AbbVie Nov 24 2014 
    Dividend Aristocrats In Focus Part 41: Abbott Laboratories (ABT) Nov 17 2014 
    Sure Bets: Slow-Changing Industries for Long-Term Investors Oct 01 2014 


    More From Other Websites
    Mylan inversion deal completed Feb 27 2015
    Interested In Pharmaceutical Stocks? Try Novartis (ADR) Feb 27 2015
    Will Mylan (MYL) Beat Earnings on New Product Launches? - Analyst Blog Feb 27 2015
    ABBOTT LABORATORIES Files SEC form 10-K, Annual Report Feb 27 2015
    Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics... Feb 27 2015
    Compelling Financial Benefit in Valeant's Latest Buy Feb 27 2015
    Allergan: A new position for Glenview Capital Management Feb 25 2015
    3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis Feb 23 2015
    Three Top Stocks Break Out As Market Stages Reversal Feb 20 2015
    Abbott Declares 365th Consecutive Quarterly Dividend Feb 20 2015
    D.E. Shaw ups its position in AbbVie Feb 20 2015
    How to Build a Better Network at Work Feb 20 2015
    Billionaire Bill Ackman’s Top Picks: Allergan Inc. (AGN), Air Products & Chemicals Inc. (APD),... Feb 19 2015
    AbbVie Boosts Dividend 4% Feb 19 2015
    Abbott to Present at Cowen and Company 35th Annual Health Care Conference Feb 19 2015
    Time to Take Another Look at Oculus Innovative Sciences Feb 18 2015
    5 Trade Ideas for Tuesday: Abbott Labs, Cheniere, Biomarin, Tractor Supply & Rockwell Automation Feb 16 2015
    Zoetis Profit Up 20%, 2015 Outlook Cut Slightly Feb 11 2015
    Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog Feb 11 2015
    Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog Feb 10 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK